Collegium Pharmaceutical, Inc. (COLL) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

16/25

Growth 5 Margin 1 Expansion 5 Platform 1 Financial 4

latest quarter score

Earnings Reports

16
Collegium (COLL) Q2 2026: ADHD Portfolio Revenue Jumps 41% as Astaris Integration Accelerates Diversification
August 06, 2026
18
Collegium (COLL) Q1 2026: Jornay PM Revenue Climbs 36%, ADHD Portfolio Set for Acceleration
May 07, 2026
19
Collegium Pharmaceutical (COLL) Q4 2025: Journée PM Revenue Surges 48%, Anchoring Portfolio Diversification
February 26, 2026
20
Collegium (COLL) Q3 2025: Journay PM Revenue Jumps 46% as ADHD Franchise Accelerates
November 06, 2025
21
Collegium (COLL) Q2 2025: Jornay PM Drives 23% Rx Growth, Powering Guidance Raise and Portfolio Durability
August 07, 2025
16
Collegium (COLL) Q1 2025: Jornay Scripts Up 24% as ADHD Expansion Outpaces Pain Portfolio
July 05, 2025
Collegium Pharmaceutical (COLL) Q4 2024: Jornay PM Prescriptions Surge 29%, Paving Way for 34% Revenue Growth in 2025
February 27, 2025

Browse all companies